Get started
Author

Yuliya S. Jhanwar

Phase 1/2 study of fractionated dose lutetium‐177–labeled anti–prostate‐specific membrane antigen monoclonal antibody J591 ( 177 Lu‐J591) for metastatic castration‐resistant prostate cancer
2019 · Scott T. Tagawa, Shankar Vallabhajosula, et al. · Cancer · 144
PDF
The role of PET in lymphoma.
2006 · Yuliya S Jhanwar, David J Straus · PubMed · 138
Pharmacokinetic Assessment of the Uptake of 16β-18F-Fluoro-5α-Dihydrotestosterone (FDHT) in Prostate Tumors as Measured by PET
2010 · Bradley J. Beattie, Peter M. Smith-Jones, et al. · Journal of Nuclear Medicine · 120
PDF
Neuropeptide Y projection from arcuate nucleus to parvocellular division of paraventricular nucleus: specific relation to the ingestion of carbohydrate
1993 · Meena Jhanwar-Uniyal, Bernard Beck, et al. · Brain Research · 120
Developmental patterns of macronutrient intake in female and male rats from weaning to maturity
1991 · Sarah F. Leibowitz, Dolores J. Lucas, et al. · Physiology & Behavior · 85
Radioimmunotherapy of Metastatic Prostate Cancer with 177Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody
2015 · Shankar Vallabhajosula, Anastasia Nikolopoulou, et al. · Current Radiopharmaceuticals · 84
Current status of therapy of solid tumors.
2005 · Yuliya S Jhanwar, Chaitanya Divgi · PubMed · 57
Phase I trial of docetaxel plus lutetium-177-labeled anti–prostate‐specific membrane antigen monoclonal antibody J591 (177Lu‐J591) for metastatic castration‐resistant prostate cancer
2020 · Jaspreet S. Batra, Muhammad Junaid Niaz, et al. · Urologic Oncology Seminars and Original Investigations · 55
PDF
Pilot Study of Hyperfractionated Dosing of Lutetium-177–Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (177Lu-J591) for Metastatic Castration-Resistant Prostate Cancer
2020 · Muhammad Junaid Niaz, Jaspreet S. Batra, et al. · The Oncologist · 41
PDF
Phase I dose-escalation study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).
2018 · Scott T. Tagawa, Shankar Vallabhajosula, et al. · Journal of Clinical Oncology · 22
Prostate-Specific Membrane Antigen Is a Potential Antiangiogenic Target in Adrenocortical Carcinoma
2016 · Michael J. P. Crowley, Theresa Scognamiglio, et al. · The Journal of Clinical Endocrinology & Metabolism · 22
68Ga-PSMA-HBED-CC PET/MRI is superior to multiparametric magnetic resonance imaging in men with biochemical recurrent prostate cancer: A prospective single-institutional study
2021 · Juana Martinez, Kritika Subramanian, et al. · Translational Oncology · 18
PDF
Phase I trial of docetaxel/prednisone plus fractionated dose radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody 177lu-J591 in patients with metastatic, castration-resistant prostate cancer (mCRPC).
2014 · Scott T. Tagawa, Young E. Whang, et al. · Journal of Clinical Oncology · 10
Final results of 2-dose fractionation of 177Lu-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC).
2016 · Scott T. Tagawa, Jaspreet Batra, et al. · Journal of Clinical Oncology · 9
99mTc-MIP-1404 Planar and SPECT scan: Imaging biomarker of androgen receptor (AR) signaling and prostate specific membrane antigen (PSMA) expression.
2016 · Shankar Vallabhajosula, Yuliya Jhanwar, et al. · Journal of Nuclear Medicine · 9
Invasive granulomatous cryptococcal sinusitis in an adult with multiple myeloma
2016 · Richard A. Ferraro, Jana Ivanidze, et al. · Clinical Imaging · 7
Phase I dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC)
2018 · S.T. Tagawa, S. Vallabhajosula, et al. · Annals of Oncology · 5
Fractionated dose radiolabeled antiprostate specific membrane antigen (PSMA) radioimmunotherapy (177Lu-J591) with or without docetaxel for metastatic castration-resistant prostate cancer (mCRPC).
2015 · Jaspreet S Batra, Beerinder S Karir, et al. · Journal of Clinical Oncology · 4
Reasons for Discordance between 68Ga-PSMA-PET and Magnetic Resonance Imaging in Men with Metastatic Prostate Cancer
2024 · Jade Wang, Elisabeth O’Dwyer, et al. · Cancers · 3
PDF
Plasma Cell Myeloma Presenting With Amyloid-Laden Crystal-Negative Histiocytosis
2020 · Marc J Braunstein, Kseniya Petrova-Drus, et al. · American Journal of Clinical Pathology · 3
Anti-prostate-specific membrane antigen (PSMA) monoclonal antibody (mAb) J591 immunotherapy for prostate cancer
2016 · S.T. Tagawa, D. Scherr, et al. · Annals of Oncology · 3
Association of noninvasive, radiographic measurement of prostate-specific membrane antigen (PSMA) expression with response to PSMA-targeted radionuclide therapy (TRT).
2019 · Panagiotis J. Vlachostergios, Muhammad Junaid Niaz, et al. · Journal of Clinical Oncology · 2
Mp50-19 Dose-fractionated Anti-psma Radioimmunotherapy ( 177 Lu-j591) for Mcrpc
2016 · Jaspreet S. Batra, Beerinder Karir, et al. · The Journal of Urology · 2
PDF
Abstract CT413: Lutetium-177-labeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) for metastatic non-prostate solid tumors
2014 · Orrin Pail, Gurveen Kaur, et al. · Cancer Research · 2
Sequential intensive chemotherapy followed by autologous or allogeneic transplantation for refractory lymphoma
2021 · Nina Orfali, Yuliya Jhanwar, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 1
Works count: 34
Citation count: 972
H-index: 12
I10-index: 13
Year
Topic
Type